Business Description
INmune Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45782T1051
Total Employee Number:
21Description
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.1 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -54.3 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 7.8 | |||||
3-Year FCF Growth Rate | 9 | |||||
3-Year Book Growth Rate | -35.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.71 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.84 | |||||
9-Day RSI | 76.79 | |||||
14-Day RSI | 72.27 | |||||
3-1 Month Momentum % | 13.29 | |||||
6-1 Month Momentum % | 20.9 | |||||
12-1 Month Momentum % | -25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.04 | |||||
Quick Ratio | 4.04 | |||||
Cash Ratio | 3.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14 | |||||
Shareholder Yield % | -1.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -29922 | |||||
OCF Margin % | -29922 | |||||
ROE % | -78.2 | |||||
ROA % | -59 | |||||
ROIC % | -624.42 | |||||
3-Year ROIIC % | 23.05 | |||||
ROC (Joel Greenblatt) % | -1039.59 | |||||
ROCE % | -83.85 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1222.5 | |||||
PB Ratio | 3.3 | |||||
Price-to-Tangible-Book | 3.3 | |||||
EV-to-EBIT | -2.52 | |||||
EV-to-EBITDA | -2.54 | |||||
EV-to-Revenue | 1017.1 | |||||
EV-to-Forward-Revenue | 1.95 | |||||
EV-to-FCF | -3.4 | |||||
Price-to-GF-Value | 1.39 | |||||
| Price-to-Net-Current-Asset-Value | 3.88 | |||||
| Price-to-Net-Cash | 5.69 | |||||
Earnings Yield (Greenblatt) % | -39.68 | |||||
FCF Yield % | -22.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INMB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
INmune Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.05 | ||
| EPS (TTM) ($) | -0.67 | ||
| Beta | 1.0189 | ||
| 3-Year Sharpe Ratio | -0.18 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 50.75 | ||
| 14-Day RSI | 72.27 | ||
| 14-Day ATR ($) | 0.134514 | ||
| 20-Day SMA ($) | 2.0925 | ||
| 12-1 Month Momentum % | -25 | ||
| 52-Week Range ($) | 1.09 - 2.499 | ||
| Shares Outstanding (Mil) | 27.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
INmune Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
INmune Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 16:30 | In 65 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 64 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 1.90 (-2.56%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 1.90 (-2.56%) | ||
| General meeting for 2026 | 2026-06-16 10:00 | 1.28 (+0.79%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 1.52 (-1.30%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.52 (-1.30%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 16:30 | 1.12 (-6.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 1.12 (-6.67%) | ||
| Annual report for 2025 | 2026-03-26 | 1.22 (+2.52%) |
Show
Entries
INmune Bio Inc Frequently Asked Questions
What is INmune Bio Inc(INMB)'s stock price today?
The current price of INMB is $2.44. The 52 week high of INMB is $2.50 and 52 week low is $1.09.
When is next earnings date of INmune Bio Inc(INMB)?
The next earnings date of INmune Bio Inc(INMB) is 2026-10-30 Est..
Does INmune Bio Inc(INMB) pay dividends? If so, how much?
INmune Bio Inc(INMB) does not pay dividend.
Press Release
Articles on INmune Bio Inc
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus on Ebstracell
Aug 07, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers